Navigation Links
Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
Date:9/24/2008

II studies of ANA598 during 2009; and (v) expectations regarding the evolution of the market for HCV therapies. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval. In addition, Anadys' results may be affected by risks related to competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and validity of patent protection for its products, regulatory developments involving future products and its ability to obtain additional funding to support its operations. Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2007 and Anadys' Form 10-Q for the quarter ended June 30, 2008. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.


'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
2. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
5. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
6. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
7. Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients
8. Memory Pharmaceuticals and Roche Expand R3487/MEM 3454 Development Program
9. Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform
10. Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline
11. VIA Pharmaceuticals to Present at American Heart Association Scientific Sessions 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... FRANKLIN, Ohio , Jan. 15, 2014  A novel wearable ... it easy and painless for patients to self-inject prescription drugs ... of disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic ... expected to grow to $220B by 2018, according to analysts.   ...
(Date:1/14/2014)... 2014  Luminex Corporation (Nasdaq: LMNX ) today announced ... of 2013 on Monday, February 3, 2014. A press release ... of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... operating highlights and financial results for the fourth quarter and ...
(Date:1/14/2014)... , Jan. 14, 2014 The Brandeis Medical Center, led ... a premier and affordable laser tattoo removal experience with ... Brandeis, focus is in providing high quality cosmetic services with cutting ... " Southern California has seen a ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... Fla., July 5, 2011 MSC Care Management, a ... management solutions to the workers, compensation industry, has launched ... to help relieve the administrative burden for claims adjusters ... a proprietary online tool that allows for faster and ...
... Tourette Syndrome Association, Inc., (TSA) has unveiled a 115-square ... generate awareness and acceptance of all people living with ... "We Have Tourette,s But Tourette,s Doesn,t Have Us" is ... everyday with the symptoms of involuntary sounds and movements ...
Cached Medicine Technology:MSC CareConnect Provides Real-Time, Online Communication and Referral Management to Claims Professionals 2EHE International Showcases The National Tourette Syndrome Association, Inc. with Month-Long Window Display in Rockefeller Center Plaza 2
(Date:4/23/2014)... predict which patients might suffer potentially fatal side-effects from ... assesses brain scans using pattern recognition software similar to ... been developed by researchers at Imperial College London. Results ... which used the software are published in the journal ... 15 million people each year worldwide. Ischemic strokes are ...
(Date:4/23/2014)... benefits of probiotics, antioxidants and other nutritional compounds, more ... industry is getting in on the action. But legitimate ... the industry is responding with clinical research to shore ... Chemical & Engineering News (C&EN), the weekly ... M. Bomgardner, a senior editor at C&EN, writes that ...
(Date:4/23/2014)... SEATTLE, Washington, April 21, 2014 Five for-profit ... total of $1.25 million in Proof of Concept ... from ideas into commercial products, the Life Sciences ... a $300,000 Entrepreneur Mentoring Program grant to the ... a statewide advisory network to train the next ...
(Date:4/23/2014)... Effects of Midlife Occupational and Leisure Time Physical Activity ... physical activity in midlife increases the risk of mobility ... the risk. This is found in a study which ... The study was conducted at the Gerontology Research Center ... , Heavy physical labor is often repetitive, wears the ...
(Date:4/23/2014)... shown that proliferation of endogenous neural precursor cells ... and axons. From the perspective of neural plasticity, ... University in China observed the effects of functional ... proliferation and expression of basic fibroblast growth factor ... on the infarct side. The researchers found that ...
Breaking Medicine News(10 mins):Health News:Airport security-style technology could help doctors decide on stroke treatment 2Health News:Airport security-style technology could help doctors decide on stroke treatment 3Health News:LSDF announces commercialization grants and Entrepreneur Mentoring Program 2Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2
... of bird flu which had reached a feverish pitch early in ... //if the virus has actually beaten a retreat. , ... flu is dynamic in the winter months, as the virus can ... The H5N1 virus which had earlier restricted itself to Southeast Asia ...
... the University of North Carolina at Chapel Hill School of ... according to a study by an international group of researchers. ... by Dr. Carol Otey and her former student, Dr. Mana ... in Boston. Otey has shown that palladin is involved in ...
... basic symptoms associated with ovarian cancer may aid clinicians ... a new study.// This index is expected to serve ... details of this study is published in the January ... of the American Cancer Society, the study reveals that ...
... thousands of quails at a farm in Kimje.// It was ... a farm in Kimje, 262 kilometers southwest of Seoul to the ... in the farm of the latest outbreak. ,This recent ... starting with an first outbreak of highly virulent H5N1 virus on ...
... (Australia) government has decided //to toughen its laws on anti-smoking. ... carrying children. This comes in the wake of ... dies every 18 days, when exposed to cigarette smoke. ... Queenslanders Report, 2006, made these comments. ,A review ...
... University School of Medicine have found out that successful lung ... in many smokers. This study published in the December issue ... look at smoking relapse among people who were "forced" to ... found that close to half of 154 smokers who had ...
Cached Medicine News:Health News:Gene Discovered by Researchers Tied to Pancreatic Cancer 2Health News:A Basic Symptom Index For Early Detection Of Ovarian Cancer 2Health News:Lung Cancer Surgeries Doesn’t Help Breaking Nicotine Dependence in Smoker 2Health News:Lung Cancer Surgeries Doesn’t Help Breaking Nicotine Dependence in Smoker 3
... components that comprise the SmartPill GI ... comprise the SmartPill GI Monitoring System: ... Receiver software and SmartPill MotiliGI software. ... indispensable parts of the SmartPill GI ...
... for POLYGRAM NET™ (PNET) works with ... record and analyze pressure, swallow, and ... procedures. The PNET software and Polygraf ... water-perfused manometry catheters and the RespSponse™ ...
... Advanced pH Analysis for POLYGRAM NET™ ... Testing Application. Like the standard application, Advanced ... by either the Digitrapper™ Catheter-Based pH Recorder ... ,Designed primarily for use by clinical ...
Capillaries available in glass and "non-PVC" plastic. Match different analyzer requirements. Variety of sizes match sample-volume requirements of individual analyzers....
Medicine Products: